Metabolic & Incretin Research blend
CagriSema CS
Amylin + GLP-1 blend
Research blend of cagrilintide, an amylin analogue, and semaglutide, a GLP-1 receptor agonist, studied for appetite and body-weight pathways.
Evidence level. Published human clinical data exists, from trials or approved use. For a blend, the rating covers the combination itself; each component has its own profile. About the badges
- Class
- Amylin + GLP-1 blend
- Category
- Metabolic & Incretin
- Type
- Research blend
- Abbreviation
- CS
- Development and regulatory status
- Investigational; US application submitted December 2025, not yet approved
Blend composition
Cagrilintide + Semaglutide, equal doses (2.5+2.5, 5+5, 10+10 mg)
Each component is profiled separately in the catalogue: Cagrilintide, Semaglutide.
What researchers study
CagriSema combines cagrilintide, an amylin analogue, with semaglutide, a GLP-1 receptor agonist. The two act on separate satiety-related pathways, and the combination is studied for additive effects on appetite and body weight.
Research areas
- Combined amylin and GLP-1 receptor pathway studies
- Additive effects on appetite and satiety signalling
- Body-weight and glucose-handling studies in models
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- phase 3 trial
In REDEFINE 1 (3,417 adults), mean weight change at 68 weeks was -20.4% with the combination versus -3.0% with placebo
- phase 3 trial
The same trial also included cagrilintide-alone and semaglutide-alone arms, with 2,108 participants on the combination
- phase 2 trial
Cagrilintide alone: -6.0% to -10.8% at 26 weeks across groups versus -3.0% with placebo
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- Cagrilintideamylin analogue component of CagriSema
- SemaglutideGLP-1 receptor agonist component of CagriSema
